Possible pathogenic mechanisms for doxorubicin‐induced splenic atrophy in a human breast cancer xenograft mouse model
Authors:
- 29 June 2024
- journal article
- research article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 44 (10) , 1606-1615
Abstract
Doxorubicin‐based chemotherapy is a widely used first‐line treatment for breast cancer, yet it is associated with various side effects, including splenic atrophy. However, the pathogenic mechanisms underlying doxorubicin‐induced atrophy of the spleen remain unclear. This study investigates that doxorubicin treatment leads to splenic atrophy through several interconnected pathways involving histological changes, an inflammatory response, and apoptosis. Immunohistochemical and western blot analyses revealed reduced size of white and red pulp, decreased cellularity, amyloidosis, and fibrotic remodeling in the spleen following doxorubicin treatment. Additionally, increased secretion of pro‐inflammatory cytokines was detected using an antibody array and enzyme‐linked immunosorbent assay (ELISA), which triggers inflammation through the regulation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor‐kappa B (NF‐κB) signaling pathways. Further analysis revealed that the loss of regulators and effectors of the oxidative defense system, including sirtuin (Sirt)3, Sirt5, superoxide dismutase (SOD)1, and SOD2, was implicated in the upstream regulation of caspase‐dependent cellular apoptosis. These findings provide insights on the pathogenic mechanisms underlying doxorubicin‐induced splenic atrophy and suggest that further investigation may be warranted to explore strategies for managing potential side effects in breast cancer patients treated with doxorubicin.Keywords
This publication has 39 references indexed in Scilit:
- The Role of Nrf2 and Inflammation on the Dissimilar Cardiotoxicity of Doxorubicin in Two-Time Points: a Cardio-Oncology In Vivo Study Through TimeInflammation, 2023
- Galangin attenuates doxorubicin‐induced cardiotoxicity via activating nuclear factor erythroid 2‐related factor 2/heme oxygenase 1 signaling pathway to suppress oxidative stress and inflammationPhytotherapy Research, 2023
- IL-27p28 knockout aggravates Doxorubicin-induced cardiotoxicity by regulating Macrophage polarizationBiochemical Pharmacology, 2023
- Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitorsCancer Medicine, 2022
- Molecular insights into the pathophysiology of doxorubicin-induced cardiotoxicity: a graphical representationArchives of Toxicology, 2022
- Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in JapanInternational Journal of Clinical Oncology, 2020
- New molecular and biochemical insights of doxorubicin-induced hepatotoxicityLife Sciences, 2020
- Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial oxidative stressRedox Biology, 2018
- Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort studyThe American Journal of Surgery, 2015
- Cellular mechanisms for methotrexate chemotherapy-induced bone growth defectsBone, 2007